Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Keywords: Obesity, Diabetes, GLP-1 receptor agonist, Depression, Binge-eating disorder, Qualitative Introduction Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of drugs developed initially for treatment of type 2 diabetes (T2D) and then obesity, by mimicking the incretin effect which includes glucose-dependent increased insulin secretion and improved glycaemic control, and inducing weight loss in a dose-dependent manner [1]
The presence of GLP-1 therapy does not immunize patients from unrelated disease
Reduced Food Cravings For many patients, tirzepatide treatment leads to a significant reduction in food cravings, allowing them to focus on other aspects of their lives
However, restarting typically requires dose titration from a lower dose upward, which takes several weeks
Whereas GLP-1 decreases plasma glucose levels by exerting insulinotropic effects, glucagon stimulates hyperglycemia by enhancing hepatic glucose output
US$ 29.23
US$ 23.19
US$ 27.40
US$ 28.72
US$ 27.24
US$ 25.05
US$ 27.87
